RxDoctor Payments Data

Kelsie Look

Medical · Honolulu, HINPI 1275904930

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 187 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,186 and has fallen 75.0% since, to $546 in 2025.

$5,002in general payments, 2019–2025

Across 187 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$897
  • Medtronic$786
  • AbbVie$774
  • Boston Scientific$403
  • Nevro Corp.$394
  • Biotronik NRO, Inc.$294
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$5,002100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,002 in reported general payments places this provider in the 80th percentile of 63 medical providers in Hawaii.

See all medical providers in Hawaii

Medicare billing

Part B allowed, 2024
$51,662
Medicare patients
97
Services billed
6,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl52$70,243
TrintellixVortioxetine Hydrobromide16$7,096
SymproicNaldemedine Tosylate11$4,998
Morphine Sulfate ErMorphine Sulfate152$4,896
Methylphenidate Hcl46$2,295
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen66$1,922
Gabapentin85$1,646
Methadone Hcl88$1,491
Oxycodone Hcl124$1,342
Pregabalin30$1,270
Ondansetron Hcl21$473
Morphine Sulfate44$432
Venlafaxine Hcl ErVenlafaxine Hcl14$422
Ibuprofen29$319
Celecoxib15$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$164$7,09616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 63 medical providers in Hawaii.

Other medical in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →